On October 18, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in Madrid, Spain beginning on October 23, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are looking forward to sharing updates from across our pipeline at ESMO (Free ESMO Whitepaper), with seven abstracts highlighting both new clinical findings, and continued progress in our oncology programs," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. "Eikon scientists and clinicians look forward to discussing these results with the broader oncology community in Spain."
2026 ESMO (Free ESMO Whitepaper) Abstract Titles and Presentation Details:
EIK1001
Title: 2664P – TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist) plus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results from the squamous cohort and updated pooled results
Date: Monday, October 26, 2026
Time: 12:00 – 12:45
Title: 2724TiP – A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (NSCLC) [TeLuRide-008]
Date: Monday, October 26, 2026
Time: 12:00 – 12:45
EIK1003
Title: 1048P – Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors
Date: Friday, October 23, 2026
Time: 15:15 – 16:00
Title: 1049P – Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC)
Date: Friday, October 23, 2026
Time: 15:15 – 16:00
EIK1004
Title: 1060P – A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations
Date: Friday, October 23, 2026
Time: 15:15 – 16:00
EIK1005
Title: 1143eTiP – Phase 1/2 Study of the Novel Werner Helicase Inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, Including MSI-H or dMMR Tumors
ePoster
Title: 1010P – Analysis of the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor
Date: Friday, October 23, 2026
Time: 15:15 – 16:00
(Press release, Eikon Therapeutics, OCT 18, 2026, View Source [SID1234673546])